APA

Fisher J. E., Rogers M. J., Halasy J. M., Luckman S. P., Hughes D. E., Masarachia P. J., Wesolowski G., Russell R. G., Rodan G. A. & Reszka A. A. (19990301). Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. : Proceedings of the National Academy of Sciences of the United States of America.

Chicago

Fisher J E, Rogers M J, Halasy J M, Luckman S P, Hughes D E, Masarachia P J, Wesolowski G, Russell R G, Rodan G A and Reszka A A. 19990301. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. : Proceedings of the National Academy of Sciences of the United States of America.

Harvard

Fisher J. E., Rogers M. J., Halasy J. M., Luckman S. P., Hughes D. E., Masarachia P. J., Wesolowski G., Russell R. G., Rodan G. A. and Reszka A. A. (19990301). Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. : Proceedings of the National Academy of Sciences of the United States of America.

MLA

Fisher J E, Rogers M J, Halasy J M, Luckman S P, Hughes D E, Masarachia P J, Wesolowski G, Russell R G, Rodan G A and Reszka A A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. : Proceedings of the National Academy of Sciences of the United States of America. 19990301.